Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
NCT06488222Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in bladder cancer, sponsored by University of Florida. Primary endpoint: Recurrence free survival at 12 months. Started Nov 2024; status: recruiting.
02
Drugs
docetaxelgemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06488222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488222.